On May 18, the first Guangzhou Guangdong, Hong Kong and Macao Greater Bay Area Biomedicine and Health Roundtable Summit with the theme of "Dreaming of Health, Starting the Bay Area" was held in Guangzhou. At the meeting, GPHL took the lead in establishing the International Innovation and Achievement Transformation Alliance of Biomedicine and Health, released a strategic report on science and technology innovation and upgrading, and announced a number of major innovative drug projects.

　　It is reported that this conference is China in recent years, one of the higher specifications of the industry event, Huang Luqi, Xu Tao, Liu Changxiao, Tang Xican, Yin Yulong, Su Guohui, Pei Gang, Chen Yeguang, Rao Zihe and other nine "academicians" and South Korea Hanlin Academy (Science and Technology Academy) academician Kim Nam Heng, master of the National Medical Xuan Guowei, Zhou Daihan, as well as experts from the National Institute of Biomedical and Health field of scientific research institutes. Experts and scholars from national research institutes in the field of biomedicine and health gathered in Guangzhou, totaling nearly 100 people, to discuss the development of the industry.

　　Nearly 100 academicians, experts and entrepreneurs gathered in Guangzhou

　　Talking about the opportunities and challenges in the field of biomedicine and health in the Greater Bay Area.

　　Li Chuyuan, Secretary of the Party Committee and Chairman of the Board of Guangzhou Pharmaceutical Group, delivered a speech as the representative of the organizer. He said that Guangdong, Hong Kong and Macao have the same root, the same voice and the same spirit, and have strong complementarity and linkage in industry, so it is the right time for the development of biomedical health industry in the Greater Bay Area. GPHL will strive to play a leading role and provide "GP Solutions" for the construction of healthy Guangzhou, healthy Bay Area and healthy China.

　　▲Li Chuyuan, as the representative of the organizer, made a speech on the spot.

　　 Chen Yeguang, academician of the Chinese Academy of Sciences, Rao Zihe, founding chairman of the Life Science Society Consortium of the Chinese Association for Science and Technology, delivered keynote speeches, sharing their latest research results and suggestions for promoting the development of biomedicine and healthcare industry in the Guangdong-Hong Kong-Macao Greater Bay Area.

　　Baiyunshan is a leading company in the research and development of traditional Chinese medicine and traditional Chinese medicine health products in China. Baiyunshan Brain Heart Clear Tablet has made a major breakthrough in research and won the Second Prize of 2014 National Science and Technology Progress Award. It is understood that Cerebral Heart Clear Tablet is a national protected variety of traditional Chinese medicine exclusively produced by Baiyunshan Hohuang Traditional Chinese Medicine, which is selected in the Guidelines for Community Prevention and Treatment of Cerebrovascular Disease. Academician Liu Changxiao said that as a large variety of traditional Chinese medicine to prevent and treat cardiovascular and cerebrovascular diseases, the exclusive product Cerebro-Cardio-Clear is "very distinctive" because of the single source of drugs and stable supply of raw materials, so the clinical foundation is good, and its performance is relatively mature over the years.

　　As a high-tech product of Guangdong Province and a famous proprietary Chinese medicine product of Guangzhou City, Baiyunshan Compound Danshen Tablet's scientific research project gathers medical resources of Guangdong, Hong Kong and Macao Bay Area, as well as top-notch medical talents from home and abroad, and in 2012, the project of "Research on the Role and Mechanism of Baiyunshan Compound Danshen Tablet in Preventing and Combating Alzheimer's Disease" became the first project of the "Father of Viagra", which is the most famous Chinese medicine product in China. In 2012, the project of "Research on the Effect and Mechanism of Baiyunshan Compound Danshen Tablets in Preventing Alzheimer's Disease" became the first contracted research project of Dr. Murad, the father of Viagra and Nobel Prize Laureate, who helped Baiyunshan Compound Danshen Tablets to carry out secondary development.

　　Academician Su Guohui, an expert at the meeting, said that Baiyunshan Compound Danshen Tablets contain danshen, which is conducive to the protection of cerebrovascular health. It is reported that Compound Danshen Tablet activates blood circulation, removes blood stasis, regulates qi and relieves pain, and is a first-class drug for the prevention of cardiovascular diseases. Years of clinical trials have confirmed the unique effect of this product in the prevention and treatment of Alzheimer's disease, which can be used for the loss of intelligence or forgetfulness caused by stasis blocking the brain complex; it can improve the cognition, language, behavior and daily life ability of patients with vascular dementia. The product has been awarded more than ten patents, including the patent for prevention and treatment of Alzheimer's disease and the patent for scientific proportioning of various active ingredients.

　　3 Nobel Prize winners, more than 20 academicians and experts to join the

　　Guangzhou Pharmaceutical Group is committed to building a world-class enterprise

　　As a leading enterprise in Guangzhou's biomedical health industry, Guangzhou Pharmaceutical Group has made significant breakthroughs in recent years in the construction of scientific research platforms, training of scientific and technological personnel, major projects, and industry-academia-research synergies. During the "Thirteenth Five-Year Plan" period, Baiyunshan Hehuang Traditional Chinese Medicine undertook 26 projects or subsidies from the government at national, provincial and municipal levels, applied for 35 patents (including 24 inventions and 1 PCT), authorized 20 patents (including 12 inventions), and 3 invention patents were awarded the China Patent Award of Excellence. In addition, Baiyunshan Hohhuang Traditional Chinese Medicine established a national post-doctoral research station as early as 2008, and has established multi-level cooperative relationships with the University of Hong Kong, the University of Macau, the Macau University of Science and Technology, etc., forming a relatively complete industrial chain that promotes the rapid transformation of scientific research results.

　　Since 2007, Guangzhou Baiyunshan Hutchison Whampoa Traditional Chinese Medicine Co., Ltd. and a team of experts and academicians joined hands to build the "State Key Laboratory of Respiratory Diseases", after more than 10 years of joint research, the research team found that: Baiyunshan Panlangen active ingredients such as polysaccharides, lignans, and indole, etc. have the dual efficacy of antiviral and anti-inflammatory drugs.

　　In October 2020, Baiyunshan Hohhuang Traditional Chinese Medicine signed a "Memorandum of Understanding on the Transformation of Baiyunshan Panlangen Research Results in Macao" with Guangzhou Pharmaceutical Group (Macao) International Development Industry Company Limited, Guangzhou Respiratory Health Research Institute and Macao University of Science and Technology. The scientific research results of Baiyunshan Panlangen and Compound Panlangen will be industrialized in Macao, becoming the first project after the establishment of the Macao International Headquarters of Guangzhou Pharmaceutical Group. At present, Baiyunshan Banlangen has made new breakthroughs in its secondary development, and is expected to be developed into a new Chinese medicine with a higher level of quality control and stronger efficacy. The project has completed the design and registration of the outer packaging of the Macau version of Banlangen, and has obtained the "Advance License for Importation of Traditional Medicines" in Macau, and is preparing for the construction of a production base in Macau's Green Island Industrial Park.

　　Li Chuyuan said that Guangzhou has a good market environment, many development opportunities and plenty of space, and will seize the opportunity of the new round of reform and opening up in Guangzhou, especially the high-end agglomeration of biomedical and health industries in Guangdong, Hong Kong and Macao Bay Area, and will continue to strengthen and deepen the cooperation with domestic and foreign universities, scientific research institutes, healthcare institutions, and external complementary enterprises, to enhance the innovation ability and international competitiveness, and make contributions to the creation of the highland of biomedical and health industries in Guangdong, Hong Kong and Macao Bay Area. We will make contribution to the development of biomedical health industry in Guangdong, Hong Kong and Macao Bay Area.